Early Exanthema Upon Vemurafenib Plus Cobimetinib Is Associated With a Favorable Treatment Outcome in Metastatic Melanoma: A Retrospective Multicenter DeCOG Study

BACKGROUND: The combination of BRAF and MEK inhibitors has become standard of care in the treatment of metastatic BRAF V600-mutated melanoma. Clinical factors for an early prediction of tumor response are rare. The present study investigated the association between the development of an early exanth...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Front Oncol
Autors principals: Kähler, Katharina C., Gutzmer, Ralf, Meier, Friedegrund, Zimmer, Lisa, Heppt, Markus, Gesierich, Anja, Thoms, Kai-Martin, Utikal, Jochen, Hassel, Jessica C., Loquai, Carmen, Pföhler, Claudia, Heinzerling, Lucie, Kaatz, Martin, Göppner, Daniela, Pflugfelder, Annette, Bohne, Ann-Sophie, Satzger, Imke, Reinhardt, Lydia, Placke, Jan-Malte, Schadendorf, Dirk, Ugurel, Selma
Format: Artigo
Idioma:Inglês
Publicat: Frontiers Media S.A. 2021
Matèries:
Oncology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8183381/
https://ncbi.nlm.nih.gov/pubmed/34109122
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2021.672172
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars